Evoke Pharma

Shareholders of Evoke voted at a court-ordered meeting to approve Bally’s Intralot’s recommended share-swap offer; the vote tallied 268,206,379 yes to 236,504 no votes (equivalent to 59.55% of the issued ordinary share capital). At the general meeting a special resolution to implement the transaction and amend the articles of association was also passed. Several antitrust and regulatory conditions have been satisfied; a court approval and the scheme’s effectiveness are expected in Q4 2026 or Q1 2027. » Plus sur de.investing.com

Evoke confirms a recommended all‑share takeover offer from Bally’s Intralot with an implied value of 52 pence per share and total consideration of around £243.1 million. The offer represents a 33.8% premium to the pre‑announcement price; shareholders can choose between new Intralot shares or 52 pence in cash per share. The Evoke board regards the offer as fair and reasonable, and the financing is backed by a bridge facility with Deutsche Bank and Jefferies. The stock rose about 13.8% to 45.53 pence following the recommendation but remains below the offer price until regulatory approvals are obtained. » Plus sur de.investing.com

QOL Medical has completed its acquisition of Evoke Pharma; Evoke has become a wholly owned subsidiary of the buyer. QOL‑EOS Merger Sub offered $11.00 per share (a 139.7% premium), and about 67.63% of outstanding shares were validly tendered, satisfying the merger conditions. Evoke has applied to terminate its NASDAQ listing, plans to withdraw its SEC registration and intends to cease reporting obligations. Upon closing of the merger, all former Evoke directors resigned, and several executives will leave their roles in mid‑December 2025. » Plus sur de.investing.com